Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...

A study from researchers at the University of Michigan and the University of California San Diego has shed light on a ...

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 ...

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation and a Flatiron ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

San Antonio - Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 47th annual San ...